Author Correction: Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphoma

被引：0
|
作者：
Jennifer N. Brudno
Norris Lam
Danielle Vanasse
Yueh-wei Shen
Jeremy J. Rose
John Rossi
Allen Xue
Adrian Bot
Nathalie Scholler
Lekha Mikkilineni
Mark Roschewski
Robert Dean
Raul Cachau
Philippe Youkharibache
Rashmika Patel
Brenna Hansen
David F. Stroncek
Steven A. Rosenberg
Ronald E. Gress
James N. Kochenderfer
机构：
[1] Experimental Transplantation and Immunotherapy Branch,
[2] Center for Cancer Research,undefined
[3] National Cancer Institute (NCI),undefined
[4] National Institutes of Health (NIH),undefined
[5] Kite Pharma,undefined
[6] Medical Oncology/Hematology Fellowship Program,undefined
[7] NCI,undefined
[8] Lymphoid Malignancy Branch,undefined
[9] Center for Cancer Research,undefined
[10] NCI,undefined
[11] NIH Bethesda,undefined
[12] Cleveland Clinic Taussig Cancer Center,undefined
[13] Advanced Biomedical Computational Science,undefined
[14] Frederick National Laboratory for Cancer Research,undefined
[15] Cancer Data Science Lab,undefined
[16] Center for Cancer Research,undefined
[17] National Cancer Institute,undefined
[18] National Institutes of Health,undefined
[19] Office of Regulatory Affairs,undefined
[20] NCI,undefined
[21] NIH,undefined
[22] Center for Cellular Engineering,undefined
[23] Clinical Center,undefined
[24] NIH,undefined
[25] Surgery Branch,undefined
[26] Center for Cancer Research,undefined
[27] NCI,undefined
[28] NIH Bethesda,undefined
来源：
Nature Medicine | 2020年 / 26卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
引用
收藏
页码：803 / 803
相关论文
共 50 条
  • [1] Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphoma
    Brudno, Jennifer N.
    Lam, Norris
    Vanasse, Danielle
    Shen, Yueh-wei
    Rose, Jeremy J.
    Rossi, John
    Xue, Allen
    Bot, Adrian
    Scholler, Nathalie
    Mikkilineni, Lekha
    Roschewski, Mark
    Dean, Robert
    Cachau, Raul
    Youkharibache, Philippe
    Patel, Rashmika
    Hansen, Brenna
    Stroncek, David F.
    Rosenberg, Steven A.
    Gress, Ronald E.
    Kochenderfer, James N.
    NATURE MEDICINE, 2020, 26 (02) : 270 - +
  • [2] Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphoma
    Jennifer N. Brudno
    Norris Lam
    Danielle Vanasse
    Yueh-wei Shen
    Jeremy J. Rose
    John Rossi
    Allen Xue
    Adrian Bot
    Nathalie Scholler
    Lekha Mikkilineni
    Mark Roschewski
    Robert Dean
    Raul Cachau
    Philippe Youkharibache
    Rashmika Patel
    Brenna Hansen
    David F. Stroncek
    Steven A. Rosenberg
    Ronald E. Gress
    James N. Kochenderfer
    Nature Medicine, 2020, 26 : 270 - 280
  • [3] Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphoma (vol 26, pg 270, 2020)
    Brudno, Jennifer N.
    Lam, Norris
    Vanasse, Danielle
    Shen, Yueh-wei
    Rose, Jeremy J.
    Rossi, John
    Xue, Allen
    Bot, Adrian
    Scholler, Nathalie
    Mikkilineni, Lekha
    Roschewski, Mark
    Dean, Robert
    Cachau, Raul
    Youkharibache, Philippe
    Patel, Rashmika
    Hansen, Brenna
    Stroncek, David F.
    Rosenberg, Steven A.
    Gress, Ronald E.
    Kochenderfer, James N.
    NATURE MEDICINE, 2020, 26 (05) : 803 - 803
  • [4] HUMAN BINDING DOMAINS REDUCE NEUROTOXICITY OF ANTI-CD19 CAR-T CELLS
    不详
    CANCER DISCOVERY, 2020, 10 (03) : 338 - 338
  • [5] Safety and feasibility of anti-CD19 CAR T cells expressing inducible IL-7 and CCL19 in patients with relapsed or refractory large B-cell lymphoma
    Wen Lei
    Ai Zhao
    Hui Liu
    Chunmei Yang
    Cheng Wei
    Shanshan Guo
    Zhilu Chen
    Qunyi Guo
    Linjie Li
    Mingzhe Zhao
    Gongqiang Wu
    Guifang Ouyang
    Ming Liu
    Jinyi Zhang
    Jimin Gao
    Wenbin Qian
    Cell Discovery, 10
  • [6] Safety and feasibility of anti-CD19 CAR T cells expressing inducible IL-7 and CCL19 in patients with relapsed or refractory large B-cell lymphoma
    Lei, Wen
    Zhao, Ai
    Liu, Hui
    Yang, Chunmei
    Wei, Cheng
    Guo, Shanshan
    Chen, Zhilu
    Guo, Qunyi
    Li, Linjie
    Zhao, Mingzhe
    Wu, Gongqiang
    Ouyang, Guifang
    Liu, Ming
    Zhang, Jinyi
    Gao, Jimin
    Qian, Wenbin
    CELL DISCOVERY, 2024, 10 (01)
  • [7] Risk of hepatitis B reactivation is controllable in patients with B-cell lymphoma receiving anti-CD19 CAR T cell therapy
    Liu, Wei
    Huang, Wenyang
    Wang, Min
    Lv, Rui
    Li, Jian
    Wang, Ying
    Deng, Shuhui
    Yi, Shuhua
    Liu, Hong
    Rao, Qing
    Xu, Yingxi
    Lv, Lulu
    Qiu, Lugui
    Zou, Dehui
    Wang, Jianxiang
    BRITISH JOURNAL OF HAEMATOLOGY, 2020, 191 (01) : 126 - 129
  • [8] Anti-CD19 CAR T-Cell Therapy for B-Cell Non-Hodgkin Lymphoma
    Abramson, Jeremy S.
    TRANSFUSION MEDICINE REVIEWS, 2020, 34 (01) : 29 - 33
  • [9] Anti-CD19 CAR T Cells in CNS Diffuse Large-B-Cell Lymphoma
    Abramson, Jeremy S.
    McGree, Brianne
    Noyes, Sarah
    Plummer, Sean
    Wong, Curtis
    Chen, Yi-Bin
    Palmer, Edwin
    Albertson, Tina
    Ferry, Judith A.
    Arrillaga-Romany, Isabel C.
    NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (08): : 783 - 784
  • [10] Phenotypic Composition of Commercial Anti-CD19 CAR T Cells Affects In Vivo Expansion and Disease Response in Patients with Large B-cell Lymphoma
    Monfrini, Chiara
    Stella, Federico
    Aragona, Vanessa
    Magni, Martina
    Ljevar, Silva
    Vella, Cristina
    Fardella, Eugenio
    Chiappella, Annalisa
    Nanetti, Francesca
    Pennisi, Martina
    Dodero, Anna
    Guidetti, Anna
    Corradini, Paolo
    Carniti, Cristiana
    CLINICAL CANCER RESEARCH, 2022, 28 (15) : 3378 - 3386
12345